3Morena M, Cristol J P, Canaud B. Why hemodialysis patients are in a prooxidant state? What could be done to correct the pro/ antioxiclant imbalance[J]. Blood Purif, 2000,18(3) : 191-199.
4Zachara B A, Adamowicz A, Tra{ikowska U, et al. Decreased plasma glutathione peroxidase activity in uremic patients [J].Nephron,2000,84(3):278 281.
5Nakamura M, Ando Y, Sasada K, et al. Role of extracellular superoxide dismutase in patients under maintenance hemodialysis[J].NephronClin Pract,2005,101(3):cl09 115.
6Gbandjaba N Y, Ghalim N, Hassar M, et al. Paraoxonase activity in healthy, diabetic, and hemodialysis patients[J]. Clin Biochem,2012,45(6) :470-474.
8Arena A, Stassi G, Iannello D, et al. Both IL-113 and TNF-1 regulate NGAL expression in polymorphonuclear granulocytes o1 chronic hemodialysis patients[J]. Mediators Inflamm, 2010:613937.
9London G M, Marty C, Marchais S J, et al. Arterial calcifications and bone histomorphometry in end stage renal disease[J]. J Am Soc Nephrol,2004,15(7):1943-1951.
10Brancaccio D, Cozzoline M, Gallieni M. Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach [J]. J AmSocNephrol,2004,15(Suppl):s21- 24.
